Our findings indicate that the widely available markers such as serum cystatin C, urine IgG, transferrin, and NGAL may help in early assessment of kidney disease in T2DM patients, although large prospective studies are needed to confirm the conclusion. This evidence concerns the gene LCN2 and type 2 diabetes mellitus.